611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Excess Weight May Raise Rosacea RiskDecline in Antibiotic Use in Livestock Isn't Enough, Critics SayCould a Hot Cup of Tea Preserve Your Vision?Breathing Retraining Beneficial in Patients With AsthmaZika Babies Facing Increasing Health Problems With AgeHealth Tip: Dental Association Supports Fluoridated WaterAnother Legacy of Terror Attacks: MigrainesRain May Not Cause Achy Joints After AllDisrupted Sleep Linked to Increased Amyloid-β ProductionAtherosclerosis ID'd in Many Without CV Risk FactorsArtificial Intelligence Promising for CA, Retinopathy DiagnosesFirst Drug Approved for Rare Condition That Inflames Blood VesselsProtecting Your Health From Wildfire SmokeHealth Tip: Recognize Warning Signs of HypothermiaNew Hope for Kids With Multiple Food AllergiesFew Patients, Providers Discuss Costs of Glaucoma Medicationsβ-Cell Sensitivity to Glucose Impaired After Gastric BypassHow to Perk Up the Holidays for Hospital PatientsVigorous Exercise May Help Slow Parkinson's DiseaseIf Mom Has Rheumatoid Arthritis, Baby May Develop It, TooNew Gene Therapy May Be Cure for 'Bubble Boy' DiseaseAnother Gene Therapy Breakthrough Against HemophiliaPrenatal Sugar Intake May Increase Asthma Risk in OffspringObesity May Be Tied to Higher Rosacea Risk in WomenGot Scabies? Here's What to DoAre Women With Parkinson's at a Disadvantage?Bariatric Surgery Alters Liver Fatty Acid MetabolismORBIT Bleeding Risk Score Performs Best in A-FibHealth Tip: Prevent the Spread of NorovirusAre Good Kidneys Going to Waste?Metabolic Risk Factors Linked to Severe Liver DiseaseImpaired White Matter Integrity for Depression in Parkinson'sHave Eczema? No Need for Bleach Baths, Study SuggestsPowerful Clot-Busting Drugs Not Useful After Leg Blockages: StudyComing Soon: A Gel That Could Help Save Soldiers' EyesGene Therapy May Allow Hemophilia Patients to Go Without MedsThyroidectomy-Specific Quality Improvement Measures ID'dPatients OK With Fewer Opioids After Gallbladder SurgeryShhhh! Patients Are SleepingDiagnostic Mutations ID'd in Chronic Kidney Disease PatientsAntithrombotics Deemed Safe in Carpal Tunnel Release SurgeryLink Between Diabetes, Antibiotic Use Called Into QuestionHealth Tip: Diagnosing PneumoniaNoisy Commutes Could Cause Long-Lasting DamageThe Buzz on How Flies Spread DiseaseRisk of Surgical Complications Up for Overlapping Hip SurgeryOral Microbiome Composition Linked to Esophageal Cancer RiskSmartphone Pics Help Docs ID Kids' Skin ConditionEven Non-Heart Surgery May Harm Your HeartCan Scrotal Vein Condition Hike Heart Risks?
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

ABP 501, Adalimumab Biosimilar, Safe and Effective, for Psoriasis


HealthDay News
Updated: Aug 2nd 2017

new article illustration

WEDNESDAY, Aug. 2, 2017 (HealthDay News) -- The biosimilar ABP 501 has similar clinical efficacy and safety to adalimumab for the treatment of moderate-to-severe plaque psoriasis, according to a study published online July 28 in the British Journal of Dermatology.

Kim Papp, M.D., Ph.D., from Clinical Research and Probity Medical Research in Waterloo, Canada, and colleagues randomized 308 patients (1:1) to receive ABP 501 or adalimumab (40 mg) every two weeks for 16 weeks. At week 16, patients with at least 50 percent improvement from baseline in psoriasis area-and-severity index score (PASI) were eligible to continue to Week 52 (152 patients), whereas adalimumab patients were re-randomized (1:1) to continue adalimumab (79 patients) or undergo a single transition to ABP 501 (77 patients).

The researchers found that PASI percent improvements were similar across groups for weeks 16, 32, and 50 (range, 85.8 to 88.2 percent), with no significant differences across groups in percentages of PASI 50, 75, 90, and 100 responders. Similarly, changes in percent body surface area affected were similar across groups and timepoints. There were no new safety issues reported, with adverse events similar between the groups.

"ABP 501 and adalimumab have similar clinical efficacy, safety, and immunogenicity profiles over 52 weeks, including after single transition, in this patient population," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Amgen, which manufactures ABP 501 and funded the study.

Abstract
Full Text (subscription or payment may be required)